Engineering technology of implantable galvanic cells for silencing the bone-neural axis in gouty arthritis therapy

Gouty arthritis faces multiple challenges, such as recalcitrance to cure and recurrent flares, owing to its intricate pathophysiological microenvironment. Recent studies have focused on urate reduction, pain relief, or anti-inflammation effects alone, which often fail to provide satisfactory results. To address these challenges, an implantable manganese platinum microscale galvanic cell (Mn@Pt micro-GC) is developed. This system utilizes the urate oxidase-like activity of platinum to degrade deposited monosodium urate crystals, while the Mn2+ and hydrogen gas work synergistically to effectively reversing the pro-inflammatory environment. In addition to decreasing the production of pain signals associated with gout, Mn@Pt micro-GC effectively inhibits pain signal transmission along the CXCL5-neuronal CXCR2-TRPA1 axis through continuous electrical stimulation. This multimodal treatment approach emphasizes the strong relationship between bone and nerve in gout, taking into account the importance of reducing uric acid, anti-inflammation, and pain relief in gout therapy, which has led to improved treatment results. Gouty arthritis faces multiple challenges such as recalcitrance to cure and recurrent flares, with studies often focusing on urate reduction, pain relief, or anti-inflammatory effects alone. Here, authors develop a manganese platinum microscale galvanic cell as a multifunctional therapeutic strategy for the treatment of gouty arthritis.